213 related articles for article (PubMed ID: 31559573)
1. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
[TBL] [Abstract][Full Text] [Related]
2.
Wei X; Cai J; Zhuang J; Zheng B; Sui Y; Zhang G; Lin Y; Sun H
Pharmacogenomics; 2020 Jan; 21(1):43-53. PubMed ID: 31769341
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract]